Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis (2015)
- Authors:
- Autor USP: SILVA, CARLOS HENRIQUE TOMICH DE PAULA DA - FCFRP
- Unidade: FCFRP
- DOI: 10.1016/j.ejphar.2015.06.058
- Subjects: ARTERIOSCLEROSE; TERAPÊUTICA; HIDROCARBONOS AROMÁTICOS; FUMAÇA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: European Journal Pharmacology
- ISSN: 0014-2999
- Volume/Número/Paginação/Ano: v. 764, p. 118-123, 2015
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
PERNOMIAN, Larissa e SILVA, Carlos Henrique Tomich de Paula da. Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis. European Journal Pharmacology, v. 764, p. 118-123, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2015.06.058. Acesso em: 27 set. 2024. -
APA
Pernomian, L., & Silva, C. H. T. de P. da. (2015). Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis. European Journal Pharmacology, 764, 118-123. doi:10.1016/j.ejphar.2015.06.058 -
NLM
Pernomian L, Silva CHT de P da. Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis [Internet]. European Journal Pharmacology. 2015 ; 764 118-123.[citado 2024 set. 27 ] Available from: https://doi.org/10.1016/j.ejphar.2015.06.058 -
Vancouver
Pernomian L, Silva CHT de P da. Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis [Internet]. European Journal Pharmacology. 2015 ; 764 118-123.[citado 2024 set. 27 ] Available from: https://doi.org/10.1016/j.ejphar.2015.06.058 - Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms
- Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia
- Molecular modeling approaches of selective adenosine receptor type 2A agonists as potential anti-inflammatory drugs
- Identification of novel chemical entities for Adenosine receptor type 2A using molecular modeling approaches
- Química computacional no planejamento de candidatos a quimioterápicos
- Parkinson’s disease: a review from pathophysiology to treatment
- Novel chalcones derivatives with potential antineoplastic activity investigated by docking and molecular dynamics simulations
- Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase
- General aspects of lead finding and optimization in drug discovery
- Molecular dynamics, density functional theory, pharmacophore modeling, molecular interaction fields and ADME/tox investigation of novel bioactive compounds interacting with CDK2 surfaces
Informações sobre o DOI: 10.1016/j.ejphar.2015.06.058 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
